Insider Buying: Anixa Biosciences, Inc. (NASDAQ:ANIX) CEO Purchases 10,000 Shares of Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX - Get Free Report) CEO Amit Kumar acquired 10,000 shares of Anixa Biosciences stock in a transaction on Wednesday, June 4th. The shares were bought at an average price of $2.85 per share, for a total transaction of $28,500.00. Following the purchase, the chief executive officer now owns 569,925 shares of the company's stock, valued at $1,624,286.25. This represents a 1.79% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website.

Anixa Biosciences Trading Down 2.8%

Anixa Biosciences stock traded down $0.08 during midday trading on Friday, hitting $2.76. The stock had a trading volume of 80,922 shares, compared to its average volume of 90,246. The stock has a market cap of $88.90 million, a P/E ratio of -7.08 and a beta of 0.34. Anixa Biosciences, Inc. has a 12 month low of $2.07 and a 12 month high of $4.20. The business has a fifty day moving average price of $2.66 and a 200 day moving average price of $2.79.

Anixa Biosciences (NASDAQ:ANIX - Get Free Report) last announced its quarterly earnings data on Tuesday, June 3rd. The company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.10) by $0.01. On average, equities analysts anticipate that Anixa Biosciences, Inc. will post -0.41 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ANIX. D. Boral Capital reaffirmed a "buy" rating and set a $10.00 target price on shares of Anixa Biosciences in a research report on Thursday, May 29th. Maxim Group began coverage on Anixa Biosciences in a research report on Friday, March 21st. They set a "buy" rating and a $10.00 target price on the stock. Finally, HC Wainwright reaffirmed a "buy" rating and set a $7.00 target price on shares of Anixa Biosciences in a research report on Tuesday, March 25th.

Institutional Trading of Anixa Biosciences

Several hedge funds and other institutional investors have recently bought and sold shares of ANIX. Millennium Management LLC bought a new stake in Anixa Biosciences in the fourth quarter valued at about $26,000. Renaissance Technologies LLC grew its holdings in shares of Anixa Biosciences by 36.5% during the fourth quarter. Renaissance Technologies LLC now owns 14,573 shares of the company's stock valued at $34,000 after purchasing an additional 3,900 shares during the last quarter. Private Advisor Group LLC bought a new position in shares of Anixa Biosciences during the first quarter valued at approximately $35,000. Prosperity Wealth Management Inc. bought a new position in shares of Anixa Biosciences during the fourth quarter valued at approximately $54,000. Finally, Jane Street Group LLC bought a new position in shares of Anixa Biosciences during the fourth quarter valued at approximately $67,000. 29.13% of the stock is owned by institutional investors.

About Anixa Biosciences

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.